Some controversial multiple testing problems in regulatory applications.
about
Type 2 diabetes mellitus development programs in the new regulatory environment with cardiovascular safety requirementsSample size determination in group-sequential clinical trials with two co-primary endpoints.Sample size determination for a specific region in multiregional clinical trials with multiple co-primary endpoints.Group-Sequential Strategies in Clinical Trials with Multiple Co-Primary Outcomes.Sample Size Considerations in Clinical Trials when Comparing Two Interventions using Multiple Co-Primary Binary Relative Risk Contrasts.Closed Testing in Pharmaceutical Research: Historical and Recent DevelopmentsMultifunctional food: medical evidence and methodological notes on substantiating health claims.Key multiplicity issues in clinical drug development.Multiple comparisons in complex clinical trial designs.Advanced multiplicity adjustment methods in clinical trials.Sizing clinical trials when comparing bivariate time-to-event outcomes.Interim evaluation of efficacy or futility in group-sequential trials with multiple co-primary endpoints.Commentary: Changes are still needed on multiple co-primary endpoints.Multiplicity in confirmatory clinical trials: a case study with discussion from a JSM panel.Reducing unnecessary measurements in clinical trials with multiple primary endpoints.A logrank test-based method for sizing clinical trials with two co-primary time-to-event endpoints.An Application of Graphical Approach to Construct Multiple Testing Procedures in a Hypothetical Phase III Design.Sample size determination for clinical trials with co-primary outcomes: exponential event times.Graphical approaches for multiple comparison procedures using weighted Bonferroni, Simes, or parametric tests.Partition testing in confirmatory adaptive designs with structured objectives.Panel forum on multiple comparison procedures: a commentary from a complex trial design and analysis plan.A new partition testing strategy for multiple endpoints.Analysis of multiple endpoints in clinical trials: it's time for the designations of primary, secondary and tertiary to go.Test and power considerations for multiple endpoint analyses using sequentially rejective graphical procedures.The issue of multiplicity in noninferiority studies.A convenient formula for sample size calculations in clinical trials with multiple co-primary continuous endpoints.Mixture-based gatekeeping procedures in adaptive clinical trials.Sample size determination in clinical trials with multiple co-primary endpoints including mixed continuous and binary variables.Sample size adaptation in fixed-dose combination drug trial.Sample size determination in superiority clinical trials with multiple co-primary correlated endpoints.Design, data monitoring, and analysis of clinical trials with co-primary endpoints: A review.Development of gatekeeping strategies in confirmatory clinical trials.Editorial: Multiplicity issues in clinical trials.Multiplicity considerations in subgroup analysis.An enhanced mixture method for constructing gatekeeping procedures in clinical trials.Memory and other properties of multiple test procedures generated by entangled graphs.Traditional multiplicity adjustment methods in clinical trials.
P2860
Q26801121-E8AB49E1-FDED-4215-84D9-8DDB86E9F3BDQ33848180-DE858828-8C0C-4452-A7AE-844B4CD6691DQ33860355-3FA675B5-FDAC-4737-8C5E-623FDB713BFDQ35241669-BC1773D3-EF3C-4313-9163-7EDF771528D7Q35836364-907ED3B0-0012-4789-BD75-FFA55FB49D26Q36042202-F896C45F-5279-444A-934C-30863B33C3F8Q37979909-69AA2A7D-EA54-4999-B2A4-E4DADD9C4ACAQ38050330-FC24008F-3568-47FE-8513-7206E012B32FQ38101915-2A1D278C-5EB1-4DE5-BA71-05B048C3F4C1Q38150794-E6A129DD-4ACF-48D4-AFB5-9F3AB07FA6A2Q39000583-FA6D506C-38A1-4E33-A762-D641CEBA49EEQ39272947-31050A01-AFB8-432B-A510-C94FB83D9102Q39443711-EDF2DB5B-5DC5-4C59-BA0B-C0B8BE778668Q40796122-1731F083-1C9B-40CE-BA4F-C11D20D3B1D2Q40812100-4F0E1384-C030-4052-AB36-4176758DD844Q41840989-AE2D64F9-96C2-4C57-BDA4-B89EF58ECEADQ41854703-8D06768D-3BA0-476C-BD67-67B4EDF386C9Q42280280-4C5192F3-775F-43E9-8E3B-4626D29F6983Q42321286-45BD2398-9926-4183-A888-0E086E9F9573Q43853920-68262A41-16F9-4FDE-9E78-7ADF571A3288Q43878310-1C2A508D-22ED-4F42-8E92-54BC4DDAE517Q43911674-F2E5D55B-6F34-4C47-958C-3FACFB18E5DCQ44440088-3FEA5BBD-ED39-4E9D-B39B-90BB493FC57BQ45130062-D5AA6C7B-C7F9-4926-8060-68E3B1C53175Q46429258-DD8FAB7C-2265-47D3-92A7-F24AEEEFD318Q46458629-3D22662D-5830-453C-82C3-2B1B9A19FB2BQ47240098-02497394-FE70-4216-A930-633103678CA3Q47295706-470A9783-A4C8-43D9-BA8F-F5C1DF9892FEQ47306598-59B6DB60-1249-4039-899D-C7BDBE7E3EC4Q47379701-94443CA4-C718-4ACB-B7F1-E73B1F4D030EQ47691559-5983ACEA-41E8-48AE-A837-1AA11652B7B6Q48030809-344CCF05-5189-498C-B9C6-477C6B65EB51Q48270494-82B3B8D3-2456-4EEF-A272-5385EF09303DQ48315216-27478E1A-8FA3-408E-8B65-0FD1242B2988Q49846428-4310F969-3619-4C7F-BD7E-6A6FB02A173EQ50920776-63306338-1140-404F-8EC8-3EC9D0D08099Q51152686-01A1E65C-3F21-4301-AF69-D0A1186880BB
P2860
Some controversial multiple testing problems in regulatory applications.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh-hant
name
Some controversial multiple testing problems in regulatory applications.
@en
Some controversial multiple testing problems in regulatory applications.
@nl
type
label
Some controversial multiple testing problems in regulatory applications.
@en
Some controversial multiple testing problems in regulatory applications.
@nl
prefLabel
Some controversial multiple testing problems in regulatory applications.
@en
Some controversial multiple testing problems in regulatory applications.
@nl
P2860
P1476
Some controversial multiple testing problems in regulatory applications.
@en
P2093
H M James Hung
Sue-Jane Wang
P2860
P304
1-11; discussion 12-41
P356
10.1080/10543400802541693
P577
2009-01-01T00:00:00Z